Cargando…
Protocol for a double-blind randomised placebo-controlled trial of lithium carbonate in patients with amyotrophic Lateral Sclerosis (LiCALS) [Eudract number: 2008-006891-31]
BACKGROUND: Amyotrophic lateral sclerosis is a rapidly progressive neurodegenerative disorder characterised by loss of motor neurons leading to severe weakness and death from respiratory failure within 3-5 years. Riluzole prolongs survival in ALS. A published report has suggested a dramatic effect o...
Autores principales: | Al-Chalabi, Ammar, Shaw, Pamela J, Young, Carolyn A, Morrison, Karen E, Murphy, Caroline, Thornhill, Marie, Kelly, Joanna, Steen, I Nicholas, Leigh, P Nigel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3189869/ https://www.ncbi.nlm.nih.gov/pubmed/21936930 http://dx.doi.org/10.1186/1471-2377-11-111 |
Ejemplares similares
-
Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial
Publicado: (2013) -
The risk to relatives of patients with sporadic amyotrophic lateral sclerosis
por: Hanby, Martha F., et al.
Publicado: (2011) -
Amyotrophic lateral sclerosis and cerebellum
por: Kabiljo, Renata, et al.
Publicado: (2022) -
Prospective phase II study of preemptive chimerism-driven reduction of immunosuppression after non-myeloablative conditioning—Eudract #: 2007-002420-15
por: Hell, Saskia, et al.
Publicado: (2022) -
What causes amyotrophic lateral sclerosis?
por: Martin, Sarah, et al.
Publicado: (2017)